Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares
Glaukos Corp. (NYSE: GKOS) has filed a Form 144, indicating a proposed sale of 10,000 shares of common stock stemming from a Stock Option Exercise. The filing lists Fidelity Brokerage Services LLC as the broker/dealer and cites July 6, 2026, as the securities-to-be-sold date, with a past sale on April 30, 2026. This transaction involves a cash amount of $1,500,000.00 for the listed shares and $1,400,000.00 for the past sale.
Glaukos stock rating reiterated at Outperform by William Blair
William Blair has reiterated an Outperform rating on Glaukos Corporation (NYSE:GKOS) stock, which is trading near its 52-week high and is up 31% year-to-date despite recent losses. The reiteration comes as the company navigates a proposed local coverage determination (LCD) for its iDose product, with William Blair anticipating changes to the final LCD and continued solid upside in total sales, particularly from Epioxa. While analysts do not expect profitability this year, other firms like Piper Sandler, Stifel, Needham, and BTIG have also maintained positive ratings and price targets, citing Glaukos' strong pipeline and product performance.
GKOS Jumps As Glaukos Wins Bullish Targets And Trial Milestone
Glaukos Corporation (GKOS) stock surged by 7.84% following promising trial results for its glaucoma treatment, Epioxa, which also led to increased price targets from Citi and Needham. Analysts maintain an average "Buy" rating with a mean price target of $157.50, driven by the company's strong growth in micro-invasive glaucoma surgery and its deep pipeline, despite current profitability challenges. Technical analysis indicates a strong intermediate uptrend, with $140 acting as key support and potential for continuation towards $155-$160.
Glaukos stock hits 52-week high at 148.12 USD
Glaukos (GKOS) stock has reached a new 52-week high of $148.12, reflecting a 40.91% increase in value over the past year and a nearly 22% year-to-date return, despite an InvestingPro analysis suggesting it may be overvalued. The company's revenue grew 36% in Q1 2026, and it recently completed patient enrollment for a Phase 2 clinical study and received reiterated "Overweight" or "Buy" ratings from analysts like Piper Sandler, Stifel, Needham, and BTIG, with price targets ranging from $150 to $170.
GKOS (GKOS) insider sells 3,630 shares total across April and June 2026
A recent Form 144 filing indicates that Glaukos Corp (GKOS) insider Tomas Navratil sold a total of 3,630 shares across two transactions in April and June 2026, generating over $447,000. Additionally, Navratil had 716 shares vest on March 24, 2025, from restricted stock. These disclosures provide transactional details but do not specify the motivation for the sales.
Form 144 GLAUKOS Corp For: 1 July By Investing.com
This article reports on the filing of Form 144 for GLAUKOS Corp, dated July 1st. It provides various financial market data and news headlines but no further details about the Form 144 itself. The content is primarily a placeholder announcement from Investing.com.
Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares
Glaukos Corp's Chief Development Officer, Tomas Navratil, reported a tax-related share disposition. On June 25, 2026, 483 common shares were withheld by the company at $142.57 each to cover tax obligations from vested restricted stock units. Following this, Navratil directly holds 88,350 shares of GLAUKOS, which includes 38,817 unvested restricted stock units.
Form 4 Glaukos Corp For: 29 June By Investing.com
This article reports on a Form 4 filing for Glaukos Corp (GKOS) dated June 29. It notes a slight downturn in Glaukos Corp's stock and provides a financial markets overview. The piece also includes various market indices, commodity prices, and trending stock data.
Price to sales forward of Glaukos Corporation – NYSE:GKOS
This page from TradingView provides financial information for Glaukos Corporation (NYSE: GKOS), specifically focusing on its forward price-to-sales ratio. It indicates that the company is listed on the New York Stock Exchange and presents various financial and community-related sections typical of a stock analysis platform.
Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding
Glaukos Corp's CEO, Thomas William Burns, reported updated holdings of the company's common stock, primarily held through various family and charitable trusts. The update also indicated a disposition of 4,059 directly held shares at $142.57 each to cover tax obligations related to the vesting of restricted stock units. Following this transaction, Burns directly holds 68,967 shares and has 56,382 unvested restricted stock units.
Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes
Glaukos Corp. President & COO Joseph E. Gilliam had 1,056 shares of common stock withheld by the company to cover tax obligations at $142.57 per share. This tax-related disposition occurred upon the vesting and delivery of previously granted restricted stock units. Following this transaction, Gilliam directly holds 72,363 shares, which includes 41,983 unvested restricted stock units.
Price to earnings forward of Glaukos Corporation – NYSE:GKOS
The article focuses on the "Price to earnings forward" financial metric for Glaukos Corporation (NYSE: GKOS). It appears to be a stub or an incomplete data page from TradingView, indicating that the specific financial data for this metric is not yet populated or available, showing "No trades" and "Period Value Change Change %" without actual figures.
Can Glaukos (GKOS) Turn Its iLution Eyelid Platform Into a Second Growth Engine Beyond Glaucoma?
Glaukos Corporation has completed patient enrollment for its Phase 2 U.S. clinical trial of GLK-321, a physostigmine-based cream utilizing its iLution eyelid drug-delivery platform for Demodex blepharitis. This milestone represents a potential expansion for Glaukos beyond glaucoma devices into ocular surface disease and offers an early validation for its dropless iLution platform. While GLK-321 is not an immediate revenue driver, its progress is crucial for diversifying Glaukos' investment narrative and supporting future revenue growth and profitability.
Enterprise value to EBIT forward of Glaukos Corporation – NYSE:GKOS
This article provides a brief snapshot of Glaukos Corporation (NYSE: GKOS) and its Enterprise Value to EBIT forward metric. The content highlights the company's financial data available on TradingView, within the medical specialties sector. It essentially serves as a financial data point without further analysis.
Enterprise value to EBIT forward of Glaukos Corp – XETR:6GJ
This article provides financial data for Glaukos Corp (XETR:6GJ), specifically focusing on its enterprise value to EBIT forward metric. It displays "No trades" indicating no recent trading activity for the company on the Deutsche Borse Xetra. The content is primarily a data placeholder from TradingView, offering financial and market information.
Price to book forward of Glaukos Corporation – NYSE:GKOS
This article provides financial data for Glaukos Corporation (NYSE: GKOS), specifically focusing on its "Price to book forward" metric. It details the company's listing on the New York Stock Exchange and categorizes it under Health Technology and Medical Specialties. The content also notes market status and data sources.
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Glaukos Corporation has completed patient enrollment in its Phase 2 clinical study for GLK-321, an investigational drug for Demodex blepharitis. The study evaluates the safety, tolerability, and efficacy of three dose levels of GLK-321, which uses Glaukos' proprietary iLution platform for dropless transdermal drug delivery. Demodex blepharitis is a chronic eyelid disease targeted by Glaukos as a large and underserviced market.
Enterprise value to EBITDA forward of Glaukos Corp – XETR:6GJ
This article provides financial information for Glaukos Corp (XETR:6GJ), specifically focusing on its Enterprise Value to EBITDA (forward) metric. It is a brief excerpt from a financial data platform, indicating the availability of this specific valuation multiple. The content highlights the company's stock exchange listing and mentions it is a medical specialties company within the health technology sector.
What Does the Glaukos CFO's Stock Sale Really Mean for Investors
The recent sale of Glaukos Corporation (NYSE: GKOS) stock by CFO Alex R. Thurman, totaling $160,070, is likely a routine personal financial planning move rather than a negative indicator for the company, despite a broader pattern of insider selling. Glaukos shows strong revenue growth from its innovative ophthalmology products, with optimistic sales targets, though it faces ongoing operating losses and market headwinds. Analysts maintain a "Moderate Buy" rating, reflecting confidence in its long-term growth potential despite current challenges.
Glaukos completes enrollment in phase 2 blepharitis study
Glaukos Corporation has completed patient enrollment in its Phase 2 clinical study for GLK-321, a treatment for Demodex blepharitis. This milestone advances their iLution pharmaceutical platform, with GLK-321 designed for transdermal delivery of physostigmine. The company has seen its shares surge 22% year-to-date and recently reported strong first-quarter 2026 revenue growth, surpassing analyst estimates.
Glaukos Corp Actuals & Estimates (NYSE:GKOS)
This article provides an overview of Glaukos Corporation (NYSE: GKOS) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, upcoming earnings dates, recent financial results such as earnings per share and revenue, and key financial metrics like EBITDA. The article also touches on employee count and investment considerations for GKOS stock.
Glaukos Moves Into Demodex Blepharitis Space
Glaukos Corp. is venturing into the Demodex blepharitis treatment market after completing Phase 2 enrollment for a new topical cream. This move positions Glaukos to compete with Tarsus Pharmaceuticals' FDA-approved Xdemvy, which currently dominates the market. CEO Tom Burns highlighted the significant market opportunity for undiagnosed and untreated blepharitis patients.
Glaukos completes enrollment in phase 2 blepharitis study
Glaukos Corporation has completed patient enrollment in its Phase 2 clinical study for GLK-321, an investigational drug for Demodex blepharitis. The company's shares have risen 22% year-to-date, trading near a 52-week high with an $8.09 billion market capitalization. This milestone advances Glaukos' iLution pharmaceutical platform and broader ocular surface disease pipeline.
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Glaukos Corporation has completed patient enrollment in its Phase 2 clinical study for GLK-321, an investigational drug targeting Demodex blepharitis. GLK-321 utilizes the company's iLution platform for dropless transdermal delivery via an eyelid cream. The study, involving 275 patients, aims to evaluate the safety, tolerability, and efficacy of different dose levels, with primary results focusing on collarette elimination after six weeks of treatment.
Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study
Glaukos Corp (GKOS) has successfully completed patient enrollment for its Phase 2 clinical trial of GLK-321, a treatment for Demodex blepharitis, signaling a significant advancement in their ocular surface disease initiatives. With a strong GF Score™ of 81 driven by high growth potential, the company aims to address a large market with unmet needs. However, $6.5 million in insider selling over the past three months suggests some caution for investors despite its solid financial strength.
Glaukos fills 275-patient trial of eyelid-disease drug candidate
Glaukos Corporation has announced the completion of patient enrollment in its Phase 2 clinical study for GLK-321, a drug candidate for Demodex blepharitis. The study enrolled 275 patients across multiple sites in the United States to evaluate the safety, tolerability, and efficacy of three different dose levels of GLK-321, which utilizes Glaukos' proprietary iLution platform for dropless transdermal delivery. This milestone is significant for advancing Glaukos' iLution platform and addressing a large, underpenetrated market opportunity for Demodex blepharitis treatment.
Glaukos Corp (GKOS) Valuation: PE, PB & Fair Value Analysis
Glaukos Corp (GKOS) has a current valuation score of 9.72, placing it 5th out of 204 companies in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -41.71, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
GLAUKOS (GKOS) director Stapley gets 2,987 options at corrected $106.52 strike
GLAUKOS Corp director Marc Stapley was granted 2,987 stock options with a corrected exercise price of $106.52 per share. This corrects a previous Form 4 filing that mistakenly reported the exercise price as $53.57. The options, granted on May 28, 2026, vest in full on the one-year anniversary of the grant date and expire on May 28, 2036.
Glaukos (NYSE: GKOS) amends Form 4, sets option strike at $106.52
Glaukos Corp (NYSE: GKOS) has amended a Form 4 filing, clarifying that director Aimee S. Weisner was granted 2,987 stock options with an exercise price of $106.52 per share, not the previously reported $53.57. These options, granted on May 28, 2026, vest in full after one year and expire in 2036, representing a routine equity award for director compensation. This amendment corrects the exercise price for Weisner's director compensation options.
Glaukos (NYSE: GKOS) director Leana Wen awarded 2,987 stock options at $106.52
Glaukos Corp director Leana Wen was granted 2,987 stock options at an exercise price of $106.52 per share, expiring on May 28, 2036. This information was clarified in an amended Form 4/A, correcting an earlier filing that reported an incorrect exercise price of $53.57. These options were part of the company's Director Compensation Policy and will vest in full on the one-year anniversary of the grant date.
Form 4 Glaukos Corp For: 23 June
This article provides details on the Form 4 filing for Glaukos Corp, dated June 23. It states that Glaukos Corp's stock symbol is GKOS and it recently saw a 2.64% increase. The article is very brief and does not contain extensive information beyond these basic facts.
Glaukos (GKOS) corrects director option price in amended Form 4
Glaukos Corp (GKOS) has filed an amended Form 4 to correct the exercise price for 2,987 stock options granted to director Gilbert H. Kliman. The original filing on June 1, 2026, incorrectly stated the price as $53.57, but the corrected form indicates an exercise price of $106.52. These options, part of his board compensation, were granted on May 28, 2026, vest fully after one year, and expire on May 28, 2036.
Glaukos (NYSE: GKOS) director updates stock option grant to $106.52 strike
Glaukos director Mark J. Foley has updated his stock option grant, correcting the exercise price from $53.57 to $106.52 per share. This amendment was made via a Form 4/A filing, detailing a grant of 2,987 stock options that will vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. The options were granted under the company's Director Compensation Policy.
Glaukos (NYSE: GKOS) corrects strike on 2,987 director options
Glaukos (NYSE: GKOS) has filed an amended Form 4 to correct the exercise price for 2,987 stock options granted to director David F. Hoffmeister. The original filing incorrectly stated the strike price as $53.57, but the correct exercise price is $106.52. These options vest in full on the one-year anniversary of the May 28, 2026 grant date and are exercisable until May 28, 2036.
Glaukos (NYSE: GKOS) director Denice Torres granted options and corrects exercise price
Glaukos director Denice Torres was granted stock options for 2,987 shares with an exercise price of $106.52 per share, vesting one year from the May 28, 2026 grant date and expiring on May 28, 2036. This announcement corrects a previous Form 4 filing that erroneously stated the exercise price as $53.57. The options were granted under the company's Director Compensation Policy.
Form 4 Glaukos Corp For: 23 June By Investing.com
This article from Investing.com announces the filing of a Form 4 for Glaukos Corp on June 23. Form 4 filings detail changes in beneficial ownership of company stock by insiders. The article implicitly suggests investors interested in GKOS might find this information relevant, though no specific details from the Form 4 are provided within the text.
Glaukos Corp (GKOS) Financial Health: Profitability & Balance Sheet Analysis
Glaukos Corp (GKOS) has a robust financial score of 7.89, ranking 53rd in its industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 41.16% to $150.57 million, and net profit grew by 9.02%. Despite strong scores in financial health, quality of earnings, operational efficiency, growth potential, and shareholder returns, some specific financial data items have not yet been disclosed by the company.
Glaukos (GKOS) Proxy filing Summary
Glaukos (GKOS) has released its proxy filing summary, detailing the upcoming annual meeting on May 28, 2026. Shareholders will vote on director elections, executive compensation, and auditor ratification. The company reported significant growth in 2025, with 32% net sales growth, reaching $507 million, and successful product launches including iDose TR and Epioxa.
Glaukos (GKOS) Q1 2026 earnings summary
Glaukos (GKOS) reported record Q1 2026 net sales of $150.6 million, a 41% increase year-over-year, driven by strong performance in glaucoma (especially iDose TR) and corneal health. The company raised its full-year 2026 net sales guidance to $620M–$635M, reflecting confidence in its growth drivers. Despite a net loss of $19.8 million due to higher operating expenses, Glaukos ended the quarter with $280.5 million in cash and no debt.
Glaukos Stock - Analyst coverage and long-term glaucoma focus
Glaukos stock remains driven by expectations around its glaucoma and corneal health portfolio, with investors focusing on the broader analyst consensus and the company’s long-term treatment strategy. The company is positioned as a hybrid of medical device producer and specialty ophthalmic pharmaceutical platform, aiming to build a portfolio across various disease stages. Glaukos generates revenue primarily from ophthalmic medical devices for glaucoma surgery and corneal health products, with plans to add recurring revenue from ophthalmic pharmaceuticals.
Glaukos CDO Navratil sells $200,855 in company stock
Tomas Navratil, Chief Development Officer at Glaukos Corp (NASDAQ:GKOS), sold 1,537 shares of company common stock for $200,855 at a price of $130.68 per share. The sale was executed on June 16, 2026, under a Rule 10b5-1 trading plan adopted in March 2026. Despite the stock trading near its 52-week high after a 28% increase over the past year, InvestingPro analysis suggests the company is currently overvalued.
Glaukos Corp (GKOS) Institutional Confidence
Glaukos Corp (GKOS) has an institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion is 101.04%, with a slight quarter-over-quarter decrease. ETHSX is the largest institutional shareholder, holding 0.36% of outstanding shares with a significant increase in its holdings.
Glaukos CDO Navratil sells $200,855 in company stock
Tomas Navratil, Chief Development Officer at GLAUKOS Corp (NASDAQ:GKOS), sold 1,537 shares of company stock for $200,855 on June 16, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, which happened while the stock was trading near its 52-week high, Glaukos has shown strong performance with a 41% year-over-year revenue growth in Q1 2026 and positive analyst sentiment, leading to increased price targets from BTIG, Needham, and Stifel. Mr. Navratil still holds 88,833 shares, including unvested RSUs.
Glaukos (GKOS) development chief sells 1,537 shares under 10b5-1 plan
Glaukos Corp's chief development officer, Tomas Navratil, sold 1,537 shares of common stock at an average price of $130.68 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Navratil directly holds 88,833 shares, which includes 39,791 unvested restricted stock units. This insider trade was reported via an SEC Form 4 filing.
Glaukos Corp (GKOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Glaukos Corp (GKOS) based on its business segments and regional contributions. The data, updated on April 6, shows that Glaucoma contributed 82.98% ($421.07M) of the revenue, while Corneal Health accounted for 17.02% ($86.37M). Regionally, the United States was responsible for 73.91% ($375.04M) of the revenue, with International markets making up the remaining 26.09% ($132.40M).
GKOS Maintained by Needham -- Price Target Raised to $150
Needham analyst David Saxon maintained a Buy rating on Glaukos (GKOS) and increased its price target from $136.00 to $150.00, citing anticipated growth. GuruFocus indicates that GKOS is undervalued by 5.5% with a strong GF Score™ of 81/100, though insider selling of $6.5 million in the last three months warrants caution for potential investors.
Needham raises Glaukos stock price target on corneal treatment outlook By Investing.com
Needham has increased its price target for Glaukos Corporation (NYSE:GKOS) to $150 from $136, maintaining a Buy rating, citing positive outlooks on corneal cross-linking treatments despite mixed feedback on prior authorization approvals. The company reported strong Q1 2026 results with significant revenue growth and raised its full-year guidance, leading to increased analyst confidence. However, an InvestingPro tip notes that Glaukos remains unprofitable, and its stock is considered overvalued relative to its Fair Value.
Glaukos (GKOS) Truist Securities MedTech Conference 2026 Summary
Glaukos provided a summary from the Truist Securities MedTech Conference 2026, highlighting the significant growth driven by iDose, which accounted for nearly 60% of U.S. glaucoma growth in Q1, despite ongoing reimbursement clarifications. The company is actively addressing LCD process concerns regarding SLT step edits and MIGS restrictions, while also focusing on improving Medicare Advantage and commercial access for iDose. Glaukos remains confident in achieving its growth targets through increased utilization as more MACs finalize professional fee schedules and by targeting the large pool of post-SLT failure patients.
GKOS: iDose and Epioxa show strong growth amid evolving reimbursement and regulatory landscapes
Glaukos Corporation (GKOS) is experiencing strong growth in its iDose and Epioxa products. iDose continues to drive glaucoma growth, with easing reimbursement hurdles and a large eligible patient pool, despite new LCD proposal requirements. Epioxa's launch has exceeded expectations, supported by strong commercial access and a focused care network.
Glaukos (NYSE: GKOS) discloses insider sales and vesting in Form 144
Glaukos Corporation filed a Form 144 detailing proposed sales of common stock tied to restricted stock vesting and recent dispositions by one of its insiders. The filing lists upcoming vesting events for 259, 153, and 1,125 shares, along with past sales by Tomas Navratil on March 16, 2026 (1,031 shares) and April 10, 2026 (2,093 shares). This regulatory disclosure provides transparency regarding planned and completed insider transactions without detailing proceeds or purchaser information.
